Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Int J Lab Hematol. 2018 Jun;40(3):343-351. doi: 10.1111/ijlh.12795. Epub 2018 Mar 2.
Minimal residual disease (MRD) in B lymphoblastic leukemia has been demonstrated to be a powerful predictor of clinical outcome in numerous studies in both children and adults. In this study, we evaluated 86 pediatric patients with both diagnostic and remission flow cytometry studies and compared expression of CD81, CD58, CD19, CD34, CD20, and CD38 in the detection of MRD.
We evaluated 86 patients with B lymphoblastic leukemia who had both diagnostic studies and remission studies for the presence of MRD using multicolor flow cytometry. We established our detection limit for identifying abnormal lymphoblasts using serial dilutions. We also compared flow cytometry findings with molecular MRD detection in a subset of patients.
We found that we can resolve differences between hematogones and lymphoblasts in 85 of 86 cases using a combination of CD45, CD19, CD34, CD10, CD20, CD38, CD58, and CD81. Our detection limit using flow cytometry is 0.002% for detecting a population of abnormal B lymphoblasts. Comparison with MRD assessment by molecular methods showed a high concordance rate with flow cytometry findings.
Our study highlights importance of using multiple markers to detect MRD in B lymphoblastic leukemia. Our findings indicate that including both CD58 and CD81 markers in addition to CD19, CD34, CD20, CD38, and CD10 are helpful in MRD detection by flow cytometry.
在许多儿童和成人的研究中，B 淋巴母细胞白血病的微小残留病 (MRD) 已被证明是临床预后的有力预测指标。在这项研究中，我们评估了 86 例具有诊断和缓解流式细胞术研究的儿科患者，并比较了 CD81、CD58、CD19、CD34、CD20 和 CD38 在 MRD 检测中的表达。
我们评估了 86 例具有 B 淋巴母细胞白血病的患者，他们均具有诊断研究和缓解研究，以使用多色流式细胞术检测 MRD 的存在。我们使用系列稀释法确定了识别异常淋巴母细胞的检测限。我们还将流式细胞术结果与部分患者的分子 MRD 检测进行了比较。
我们发现，通过组合使用 CD45、CD19、CD34、CD10、CD20、CD38、CD58 和 CD81，我们可以在 86 例中的 85 例中分辨出血球母细胞和淋巴母细胞之间的差异。我们使用流式细胞术检测异常 B 淋巴母细胞的检测限为 0.002%。与分子方法的 MRD 评估相比，流式细胞术结果具有很高的一致性。
我们的研究强调了在 B 淋巴母细胞白血病中使用多种标志物检测 MRD 的重要性。我们的发现表明，除了 CD19、CD34、CD20、CD38 和 CD10 之外，包括 CD58 和 CD81 标志物有助于流式细胞术的 MRD 检测。
